CURRICULUM VITAE

Mark Forrest Gordon, MD, FAAN

Diplomate of the American Board of Psychiatry and Neurology
with Certification in Neurology

Fellow of the American Academy of Neurology

Senior Director
Specialty Clinical Development
Neurology and Psychiatry
Teva Branded Pharmaceutical Products R&D, Inc.
41 Moores Rd.
Frazer, PA 19355

The Industry Representative
Peripheral and Central Nervous System Drugs Advisory Committee
Food and Drug Administration, Center for Drug Evaluation and Research

Professional Experiences

Teva Branded Pharmaceutical Products R&D, Inc.
Frazer, PA
Specialty Clinical Development
Neurology and Psychiatry

May 15, 2017 to date **Senior Director**

Internal Roles

- **Global Clinical Program Leader (CPL) and Clinical Program Physician (CPP)**
  - Lead development of deutetrabenazine across indications
  - Lead development of laquinimod as a potential treatment for patients with HD
  - Effectively manage a 16-18 member multidisciplinary clinical study team in a matrix environment
  - Accountable for the leadership, strategy, clinical development, safety, compliance, quality, and interpretation of project

External Roles

- **Critical Path Institute, Huntington's Disease Regulatory Science Consortium (HD-RSC),** Nov. 2017-date
  - Teva's sole representative on the Coordinating Committee
  - Direct Teva's in-kind contributions across several task forces

- **Critical Path Institute, Coalition Against Major Diseases (CAMD), Non-member advisor**, Jan. 3, 2017-date
  - Actively contribute to strategic task forces to develop and qualify biomarkers, such as imaging (hippocampal atrophy) and cerebrospinal fluid indices, for patient enrichment in AD clinical trials
  - CAMD Informed Consent Working Group-active member-collaborate on the drafting of standard language to enable access to anonymized patient-level data and samples, support regulatory submissions, advance regulatory sciences for drug development tools, and catalyze innovative treatments.
  - CAMD Digital Biomarkers Working Group-active member-help evaluate potential digital drug development tools for possible qualification as endpoints for use in CNS clinical trials

- **Critical Path Institute, Critical Path for Parkinson's (CPP)-Non-member advisor,** Apr. 5, 2016-date
  - Contribute to strategic task force to develop disease progression models
  - Contribute to strategic task force to develop and qualify biomarkers, e.g. dopamine transporter (DAT) imaging, for enrichment pf patients with early PD in clinical trials.

- **European Medical Information Framework (EMIF)**
  - The former Co-Director of Work Package 2 (Mar. 2012-Dec. 2016) and the initiator and lead of several Alzheimer's dementia (AD) research
  - Continue to provide scientific input on several projects: characterizing the study population, defining extreme phenotypes, developing new biomarkers regarding AD, characterizing demographics, comorbidities, and medication profiles of patients with dementia, and evaluating the possible association of fatty liver disease with dementia. (Jan. 2017-date)

- **Peripheral and Central Nervous System Drugs Advisory Committee, Food and Drug Administration, Industry Representative (Nov. 2015-date)**
  - Provide medical/scientific opinion on the new drug's application for market authorization
  - Liaise with sponsor and advisory committee

Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT
Clinical Development and Medical Affairs
General Medicine, Central Nervous Systems and Established Core Products

June 2012-Dec. 30, 2016	Director
Sept. 2006-June 2012	Senior Associate Director

Internal Roles Regarding Clinical Development and Medical Affairs

- **Pipeline Products-Schizophrenia and Alzheimer's Disease (May 2011-Dec. 2016)**

- Member of the Central Nervous System Clinical Expert Group / Therapeutic Advisory Committee (2012-Dec 2016), a corporate level body charged with developing, reviewing, defining and endorsing pipeline strategy.
- The US medical and scientific representative on 10 global medical sub-teams (non-concurrent). Provided strategic advice on research and development of novel drugs to treat patients with Alzheimer's disease (AD), schizophrenia, and other neurologic and psychiatric conditions.
- The sole US-based expert in Neurology, served as the CNS subject matter expert
- Regularly provided high quality, impactful, and valued medical and scientific input regarding neuropsychiatric advancements, clinical development programs, study designs, endpoints, competitive intelligence, and potential disease targets.
- Initiator and Organizer of Oct. 2011 international advisory board on cognitive impairment in patients with schizophrenia. Presented key talks.
- Authored four Target Product Profiles
- Medical reviewer of several clinical development plans, protocols, and investigator brochures
- As the BI representative on several external research consortia, including the Critical Path Institute's Cognition Working Group (MCI, AD) and the Coalition Against Major Diseases (AD, PD), and the Innovative Medicines Initiative's European Medical Information Framework (AD) and European Prevention of Alzheimer's Disease, I regularly shared relevant and actionable information and possible implications regarding BI's clinical development strategy.
- Provided detailed guidance to US Clinical Operations on feasibility assessment and investigator / site selection for CNS clinical trials
- To develop scenarios and value drivers for the US Market, I provided Medical input to the cross-functional US Value Proposition Development Process initiatives on symptomatic treatments of cognitive impairment in schizophrenia and AD (both in 2014), disease modification treatment of AD (2015), and symptomatic treatment of schizophrenia (2016).
- Provided scientific and strategic input to the cross-functional Global Positioning Process to identify key value drivers for CNS drug development, explore future unmet needs and opportunities for differentiation, and develop positioning, while reflecting on both global and US concerns.
- To address the issue of insufficient diversity of subjects in CNS clinical trials by ensuring early planning, I drafted and received approval for a new section in the clinical development plan.
- Proactively initiated and directed the cross-functional BI Epidemiology of AD Interest Group to fill knowledge gaps regarding BI's internal projects and enhance research in the external consortia (2014-Dec. 2016).
- Initiator and Director of the US CNS Project Team (2015-Dec. 2016), a cross-functional group (15 people) to develop and implement the US pipeline strategy regarding 6 novel compounds and 10 individual projects
- As the US CNS Medical Advisor and a member of the US CNS Therapeutic Area Steering Committee (TASC) (2014-Dec. 2016), I led discussions regarding cross-functional issues involving medicine, regulatory, drug safety, clinical operations, commercial, and budgeting, achieved cross-functional alignment where possible, and delivered the US recommendations to the Global organization.

- Prepared the 2016 and 2017 CNS (Medical) Annual Operating Plans within budget.
- The Originator of BI consultancy for AD expert.
- Initiated and led cross-functional educational sessions on the disease state and BI's drug development programs regarding AD and schizophrenia (2015-2016). My presentations reached hundreds of colleagues across US and other regions and received excellent reviews.

❖ **Pipeline Products-Parkinson's Disease (2012-2016)**
- Provided key medical support to Research and Development for two compounds to be developed as potential drugs to modify the course of PD.
- The Originator and Director of the BI consultancies with two specialists on assessments of retinal structure and function in patients with PD.

❖ **Pipeline Products-Optic Atrophy (2013-2015)**
- Key scientific support to Research and Development for a compound to be developed as potential therapy to modify course of hereditary optic neuropathy.
- The Originator and Director of the BI consultancies with two specialists on assessments of retinal structure and function in patients with hereditary optic neuropathy (see entry for PD).

❖ **Pipeline Products-Pain (2010-2011)**
- Contributed target drug information and competitive intelligence to Core Value Dossier.
- US Medical representative at the US-Corporate Pain Workshop that established medical, regulatory, and commercial requirements for BI's drug development programs in pain.

❖ **Pipeline Products-Medical representative on the Central Nervous System (CNS) Marketing Pipeline Products team (2010-2011)**
- As the sole Medical representative in a pilot program to assess the value of medical participation in commercial planning early in drug development, I demonstrated the significant impact of this role, supporting subsequent inclusion of Medicine in early Pipeline Marketing discussions.

❖ **Pipeline Products-Medical reviewer of CNS in-licensing or co-development opportunities (2007-Dec. 2016)**
- Collaborated on the evaluation of 6 potential in-licensing or co-development new business opportunities for PD, insomnia, and pain, by providing medical assessment on compound efficacy and safety, target product profile, potential indications, competitive landscape, segmentation of target markets, and development program.

❖ **Team Member Medicine, Mirapex (Sifrol) ER for Parkinson's disease (2011-2014)**
- The Medical lead on international project to develop, submit, and register Mirapex ER in China for patients with PD

- Rapidly and effectively coordinated this project across international (mostly virtual) Phase I and III clinical trial teams, corporate and regional regulatory teams, and other stakeholders. Lead the execution, interpretation, and reporting of these trials.
- Developed an aligned strategy and directed the medical aspects of the New Drug Application submission to China (beating an already accelerated project timeline), resulting in the Chinese Food and Drug Administration's approval of this drug in China for patients with PD.
- Co-author and corresponding author of the Phase III trial manuscript, published in Translational Neurodegeneration, a peer-reviewed journal, in June 2014.

❖ **Medical representative on pramipexole (Mirapex and Mirapex ER) Product Label Review Team (PLRT) (2008-2014)**
- Provided accurate and timely medical input on Mirapex ER US Prescribing Information (USPI) during drafting and label negotiation, leading to drug approval.
- Helped draft, negotiate, and implement the Physician's Labeling Rule conversion of the Mirapex USPI.
- Provided accurate, timely and valuable medical expertise and guidance on many US PI issues, leading to successful submission to FDA and label changes.
- Regularly participated in Product Label Committee and International Label Committee meetings.
- Represented Medical at the Mirapex and Mirapex ER Annual Label Review.

❖ **Medical Marketing Liaison for Mirapex and Mirapex ER (2009-2014)**
- As the US Medical Advisor on Mirapex and Mirapex ER, I closely collaborated with Marketing, Regulatory, Pharmacovigilance, and Legal, and provided accurate, relevant, and timely medical insight and support to the Brand.
- As the sole Medical reviewer and as an active participant in the Medical-Legal-Regulatory review process, I critically evaluated educational and promotional materials and developed new concepts, strategies, and deliverables, in compliance with regulatory and legal requirements.

❖ **Director of the pramipexole (PPX) Phase IIIb and IV research program for Parkinson's disease (PD) (2006-2010)**
- Supervised the clinical trials team of five studies to ensure effective development, implementation, conduct, and monitoring in compliance with Good Clinical Practice.
- As the Trial Clinical Monitor of PramiBID Study, I successfully directed and completed this trial, including authorship of the electronic Clinical Trial Report, submission of the public disclosure of trial results, and critical review, co-authorship, and publication of the trial manuscript.
- Co-primary and corresponding author of a manuscript on minimal clinically important difference in PPX ER pivotal trials, published in Parkinson's Disease.
- Senior author of published manuscript on Mirapex Eye Safety Study comparing retinal safety of pramipexole and ropinirole in patients with early PD.

- **Medical representative on Mobic (meloxicam) Product Label Review Team (2010-2012)**
  - Provided accurate, timely and valuable medical expertise and guidance on many US PI issues, leading to successful submission to FDA and label changes.

- **Medical author and reviewer of regulatory documents (2007-2014)**
  - Interpreted and summarized clinical data in medical sections of regulatory documents.
  - Core member of the Mirapex ER Submission Team.
  - Authored Summary of Clinical Safety and Four-Month Safety Update for PPX ER NDA.
  - Authored medical sections of 6 PPX IND annual reports (2007-2012), covering up to 4 INDs per report.
  - Authored medical sections of 14 PPX NDA annual reports (2007-2014).
  - Completed comprehensive and timely Medical reviews of all (> 600) PPX ER case narratives for NDA submissions.
  - Authored Medical sections of NDA annual reports for Mobic tablets and oral suspension (2011-2012).

- **Reviewer, Medical grants (2010)**
  - The primary Medical reviewer of pramipexole grants.
  - Secondary Medical reviewer of hypoactive sexual desire disorder grants.

- **Assumed responsibilities of Senior Director, Consumer Health Care (CHC): (Mar. 2011-Feb. 2012)**
  - In addition to all of my existing roles, due to the unexpected resignation of the Senior Director of CHC, I rapidly took the initiative to fill the business need and seized the opportunity to expand my professional experience.
  - My contributions to CHC included:
    - Medical support of new business opportunities, such as Zantac soft gel capsule, Zantac and Dulcolax "Pink" for Women, anti-diarrheal agents, and Pharmaton herb, vitamin, and mineral supplements
    - Core Participant in CHC Development Committee Meetings
    - Zantac and Dulcolax claims development and substantiation (Medical-Legal-Regulatory review; my literature search of over 1000 articles yielded proposals for several new claims for Zantac)
    - Competitive intelligence
    - Preparation of Medical sections of selected regulatory documents (e.g. Buscopan IND annual report)
    - Product support

- **Team Member Medicine and Core Team Member, Consumer Health Care (CHC)-Zantac new business opportunity (NBO) (Mar. 2011-Feb. 2012)**
  - Medical lead and Core Team Member of international NBO to develop a bioequivalent liquid-filled soft gelatin capsule formulation of Zantac. I led project up to approval and outsourcing.
  - Authored Medical sections of the submission package.

- Developed synopses and budgets of fasted and fed bioequivalence (BE) studies
- As a reflection of the timeliness and quality of our Core Team's submission, the CHC Management Committee approved project for start of development 2-weeks ahead of the scheduled face-to-face meeting (avoiding a formal meeting), resulting in a considerable savings of time, internal resources, and expenses.
- Provided input on selection of development partner, possible outsourcing, and timelines and costs of a clinical development program. Based in part on my assessment of the advantages of BE study sponsorship by an external vendor rather than by BI, upper management approved external sponsorship, resulting in time and cost savings.

Internal Task Forces (partial listing)

- **BIPI Diversity Initiatives: Leader and Collaborator (2015-Dec. 2016)**
  - To address the need for appropriate racial/ethnic group representation in our US and global clinical trial programs and ensure relevance of the subjects' data to the targeted population with the disease in specific regions, I proposed and led a "diversity" planning initiative to create, author and obtain US and Corporate approval for new sections regarding regional diversity in the global Clinical Development Plan template and guideline.
  - I collaborated on the preparation and submission of responses to FDA dockets about the presentation of demographic subgroup data for FDA-approved products on the FDA's Internet Website (FDA Snapshot) and the inclusion of minorities in clinical trials.

- **BIPI Business Innovation Team, Digital Health Advisory Council: CNS CDMA representative (2015-Dec. 2016)**
  - Collaborated to evaluate, develop and implement innovative digital health solutions to support patients and our business. Created a software application for patients with psychiatric illness.
  - Member of the Core Team that developed plans to leverage digital health opportunities to optimize BI's drug development (2016).

- **US Prescription Medicine (LEADERS) Task Force on product development (pre-approval) and clinical trial collaboration: the CDMA representative (Feb. 2012-July 2012)**
  - Our team developed criteria for collaborations with organized customers (payers and providers), identified potential partners, and proposed pilot projects that lead to fruitful collaborations in CNS and other therapeutic areas.

External Roles

- **Peripheral and Central Nervous System Drugs Advisory Committee, Food and Drug Administration, Center for Drug Evaluation and Research: Industry Representative (acting Nov. 1, 2015 to March 17, 2016, instated March 18, 2016 to Oct. 31, 2019)**

- From perspective of industry, provide medical/scientific opinion on the new drug's application for market authorization.
- Ad hoc industry representative at the Psychopharmacologic Drugs Advisory Committee (Mar. 2016).

❖ **Innovative Medicines Initiative, European Medical Information Framework (EMIF)-Alzheimer's Disease (AD): the European Federation of Pharmaceutical Industry Associations Co-Director of Work Product 2 (Mar. 2012 to Dec. 30, 2016)**

- Co-directed Work Package 2 focusing on characterization of study population, definition of extreme phenotypes, and development of biomarkers to identify risk factors for AD pathology in asymptomatic subjects and predict progression from presymptomatic to symptomatic AD and from prodromal AD to AD-dementia.
- I organized and directed my multinational team of 30-plus academic and pharmaceutical industry scientists from 18 institutions to develop and implement research strategy, access 30+ European observational cohort and electronic health record databases, perform analyses, and interpret and report results on 21 individual research projects, yielding > 20 scientific presentations and six publications to date.
- Key projects included: developing and operationalizing a diagnostic algorithm, characterizing the study population (including prevalence of prodromal AD and AD dementia), defining the extreme phenotypes based on clinical presentation (e.g. resilience to dementia in the oldest old), cognitive markers (e.g. rate of cognitive decline), and biomarkers (e.g. beta amyloid load, hippocampal atrophy), and developing new biomarkers to identify risk factors, predict disease progression, and improve the design of interventional clinical trials.
- Regularly provided scientific results, strategic insights, and research plans to senior EMIF leadership.
- Led the identification, delineation, monitoring and reporting of project risks.
- Initiator and Leader of the EMIF-AD Cognition Task Force
- Member of the EMIF-AD Neuroimaging Task Force
- The Lead BI Scientific Representative to EMIF
- Collaborated on reporting BI's yearly financial contributions (several million Euros) and personnel (in-kind) efforts.
- Established a BI EMIF-AD Interest Group comprised of cross-functional colleagues to promote BI's involvement in EMIF-AD, identify BI's business needs, and share knowledge with potential applications to BI's AD development program.
- Initiator and Leader of EMIF Platform Use Case 13 to evaluate the demographics, comorbidities, and medication patterns of patients with dementia / AD based on several real-world electronic health record (E-H-R) databases in Europe.
- Initiator and Leader of two projects to evaluate the possible association of fatty liver disease (metabolic syndrome) with dementia, using several European E-H-R databases and a large national database.

❖ **Critical Path Institute Coalition Against Major Diseases (CAMD) (AD and PD): The BI representative on the CAMD Coordinating Committee and eight task**

forces (Mar. 2012-Dec. 2016), CAMD Industry Co-Director (Nov. 2013-Oct. 2015), Non-member advisor (Jan. 3, 2017-date)

- Identified this initiative, strongly advocated regarding the potential internal and external benefits of BI's participation, and secured approval. CAMD is a collaboration of experts from industry, academia, patient advocacy organizations, and government and regulatory agencies, dedicated to accelerating therapies for AD and PD.
- As CAMD's Industry Co-Director, I represented industry members' interests and partnered with the C-Path executive director to achieve multiple milestones, including the first regulatory endorsement of a clinical trial simulation tool.
- As BI's representative on the CAMD Coordinating Committee, I provided key scientific input, leadership, and collaboration, including setting strategy, assessing resources, and prioritizing projects and spending to develop clinical trials tools and obtain their regulatory qualification.
- Actively contributed to several strategic task forces including: development of disease progression models for AD and PD, development of qualified clinical end points, such as a cognitive outcomes assessment tool for prodromal AD, and development of qualified biomarkers for patient enrichment in clinical trials, such as imaging (hippocampal atrophy) and cerebrospinal fluid indices in AD clinical trials and imaging of the dopamine transporter (DAT) in PD clinical trials.
- Lead the core team of the Cognition Clinical Outcome Assessment Task Force to prepare the context of use statement and letter of intent for the FDA and EMA, and obtain and analyze patient-reported data for this proposal.
- The Medical and Industry Leader of the PD DAT Imaging Biomarker Core Team for the 2013 FDA BQRT advice face-to-face meeting.
- As of Oct. 2015, this Critical Path consortium split into CAMD focusing on AD and Critical Path-Parkinson's (CPP) focusing on PD.
- CAMD Informed Consent Working Group, member (2016-date). We drafted standard language to enable access to anonymized patient-level data (and samples), support regulatory submissions, advance regulatory sciences for Drug Development Tools, and catalyze innovative treatments.
- CAMD Digital Biomarkers Working Group, member (2016-date). Evaluating potential drug development tools for qualification as endpoints for use in CNS clinical trials.

❖ **Critical Path Institute, Critical Path for Parkinson's (CPP) consortium, Non-member advisor (Apr. 5, 2016-date)**

❖ **Critical Path Institute Cognition Working Group: the lead BI representative (2010-Dec. 2016)**

- Collaborated with pharmaceutical, academic, C-Path, and FDA colleagues in effort to develop and qualify patient reported outcome (PRO) tool for use in clinical trials in patients with mild cognitive impairment due to AD. Based on regulatory feedback, project shifted to performance-based outcome.
- Primary author of manuscript published in Alzheimer's & Dementia on the development of the PRO draft instrument in the qualitative research phase.

- **Innovative Medicines Initiative, European Platform to Facilitate Proof of Concept for Prevention in Alzheimer's Disease (EPOC-AD), renamed European Prevention of Alzheimer's Dementia consortium (EPAD) (2014-Dec. 2016)**
  - Identified, advocated for, and gained BI CNS commitment to participate in this public-private collaboration to establish a European platform for Proof of Concept trials in the prevention of AD (thereby reducing the risk and expense of early clinical development).
  - Contributed scientific input on study design, e.g. biomarkers, interventional study.

- **Innovative Medicines Initiative, AETIONOMY (2015-Dec. 2016)**
  - Collaborated in efforts to develop a new classification of neurodegenerative diseases (focusing on AD and PD) based on underlying mechanistic causes rather than symptoms

- **Michael J. Fox Foundation (MJFF) (2012-Dec. 2016)**
  - Identified, reviewed, and coordinated opportunities for BI to collaborate with MJFF about our PD drug development program.
  - BI's lead representative on the MJFF LRRK2 Industry Advisory Group.
  - As BI's representative on the LRRK2 Industry Summit, I collaborated with industry, academic, and MJFF colleagues about a toxicological (safety) issue.

- **Alzheimer's Association (2012-Dec. 2016)**
  - Reviewer of the neuroimaging abstracts to the 2014, 2015, and 2016 Alzheimer's Imaging Consortium meetings
  - Participant in several Alzheimer's Association Research Roundtable Meetings

- **Foundation of National Institute of Health Alzheimer's Disease Measurement Improvement Working Group: sole BI representative (2011-2013)**
  - Identified and spearheaded BI's involvement in the AD-MI Working Group to establish a "mega-community" around improving quality of care and outcomes by improving measurement in AD.
  - Active member in the 4 Work Streams: #1) Conceptual Framework, Concepts / Domains, and Operational Definitions; #2) Information Gathering/Landscape in AD; #3) Articulate Research Agenda; and #4) Communications and Dissemination.

- **Brain Health Modeling Initiative: Member (2015-2017)**
  - Our focus group applies quantitative systems pharmacology to big data to enhance biomarker discovery and drug development.
  - Coauthored 2 peer-reviewed publications in 2016

- **International Society for CNS Clinical Trials and Methodology (ISCTM), Analysis of Suicidal Behavior and Ideation Working Group: BI representative (2015-Dec. 2016)**
  - Collaborated to review the current approach to and gaps in our analysis of data regarding suicidality.
  - Focused my research on mediators and potential biomarkers of suicidality.

- Presented this work at the ISCTM Consensus Meeting on Methodological Considerations for Suicide Assessment and Clinical Trial Design.

People development:

- I successfully supervised, coached, and developed my staff according to their individual goals and skills, while striving to optimize their contributions.
- I fostered the professional development of several colleagues by inviting their participation and mentoring their roles

Clinical-Academic Experience

Hospital Appointments

2006 Voluntary Attending Physician, North Shore University Hospital and Long Island Jewish Medical Center.

1992-2006 Attending Full-time, Departments of Neurology and Psychiatry, North Shore Long Island Jewish Health System.
Promoted to Associate Attending 1998.

Academic Appointments

2000-2006 Associate Clinical Professor of Neurology, Albert Einstein College of Medicine, Bronx, NY

1994-2000 Assistant Clinical Professor of Neurology, Albert Einstein College of Medicine, Bronx, NY

1992-1994 Instructor in Neurology, Albert Einstein College of Medicine, Bronx, NY

Other Appointments/Positions

5/06 to 06/07 Principal, Professional Limited Liability Company (PLLC), General Neurology and Movement Disorders, New Hyde Park, NY

1992-2005 Director of the Movement Disorders Section, Long Island Jewish Medical Center, New Hyde Park, New York

1992-5/06 Director, Botulinum Toxin Program, Long Island Jewish Medical Center: Led a major regional tertiary referral center on Long Island for the administration of botulinum toxin injections. Instructed the technique to internal and external neurologists and physiatrists. Served as principal investigator and coauthor on about 12 studies that evaluated botulinum toxin injections to treat patients with dystonia, spasticity, migraine headaches, and other disorders.

1992-5/06 Director of the Movement Disorders Clinic, Long Island Jewish Medical Center, New Hyde Park, New York

2002-5/06 Co-Director of the General Neurology Clinic, Long Island Jewish Medical Center, New Hyde Park, New York

1995-2002 Member, Institutional Review Board, Long Island Jewish Medical Center

1997-2006 Preceptor, Resident Research, Department of Neurology, Long Island Jewish Medical Center

Post Graduate Training

1989-1991 Postdoctoral Clinical Fellow in Movement Disorders; College of Physicians and Surgeons of Columbia University, Columbia Presbyterian Medical Center, NY, NY (with Stanley Fahn, MD).

1986-1989 Resident in Neurology; University Hospital, Stony Brook and Northport VAMC. Chief Resident (1988–1989).

1985-1986 Intern in Internal Medicine; University Hospital, Stony Brook, NY and Northport Veterans Administration Medical Center (VAMC), Northport, NY

Education

University of Pennsylvania School of Medicine, Philadelphia, PA.
M.D. awarded May 1985

University of Pennsylvania College of Arts and Sciences, Philadelphia, PA.
Bachelor of Arts awarded May 1981.
Majors in Biology and Spanish.
Honors: Cum Laude with Honors distinction in both majors,
Benjamin Franklin Scholars Honor Society (Vice President),
Alpha Epsilon Delta Premedical Honor Society,
Dean's List

Specialty Certification

Diplomate of the American Board of Psychiatry and Neurology with certification in Neurology (Issued 12/93). This certification remains current.

Medical Licensure

New York State Medical License (Issued 8/12/86). This license remains current.

Professional Memberships (partial list)

- American Neurological Association (2013-date)-Member, Industry Liaison
- American Academy of Neurology (1986-date)-Active Member, changed to Fellow Member status in 2007
- Medical Advisory Board, Dystonia Medical Research Foundation, Greater New York Chapter, Inc. (1992-~2006)
- Medical Advisory Board, National Spasmodic Torticollis Association (~2000-2006)
- Parkinson's Study Group (1991-2006)
- Dystonia Study Group (1997-2006)

Awards (partial list)

- Center of Excellence designation by the National Parkinson's Foundation (2001)
- **Top Performer designation from Boehringer Ingelheim** for 2011, 2014, 2015
- Critical Path Institute's Coalition Against Major Diseases **Annual Individual Recognition Award** "for your leadership and dedication in advancing drug development for neurodegenerative diseases" (Nov. 2013)
- Critical Path Institute's Coalition Against Major Diseases **Annual Individual Recognition Award** "for your leadership and dedication in accelerating Drug Development Tools to advance treatments for neurodegenerative diseases" (Oct. 2015)
- Teva Stars Constellation Award for operational excellence, high work morale, professionalism, meeting or beating deadlines, and "going beyond the expectations of the job role" (Aug. 2018)

Research Grants

From 1996-2006, I served as the Principal Investigator on 34 Phase II, III, or IV clinical trials regarding patients with Parkinson's disease, cervical dystonia, headache, and limb spasticity. These studies were sponsored by numerous pharmaceutical companies, the Parkinson Study Group, or the Dystonia Study Group. Details are available on request.

Reviewer
Abbreviated list 2014-date. Details are available on request.

- Alzheimer's Association's Alzheimer's Imaging Consortium (AIC)-reviewed about 25 neuroimaging abstracts per year (2014-2017)

Bibliography
Original Communications in Reviewed Journals
108 published peer-reviewed articles as of April 17, 2019

Gordon, MF, Stolley P, Schinnar R. Trends in recent systemic lupus erythematosus mortality rates. Arth and Rheum 1981;24:762-69.

Ryoji M, Yamane T, Gordon MF, Kaji A. Two modes of amber codon read-through in vitro. Arch of Biochemistry and Biophysics 1985;238:636-41.

Gordon MF. New onset choreiform disorder in an adult with recent Group A beta hemolytic streptococcal pharyngitis. Journal of Neurology, Neurosurgery, and Psychiatry 1988;51:448-9.

Gordon MF, Coyle PK, Golub B. Eales' disease presenting as stroke in the young adult. Annals of Neurology 1988;24:264-266.

Gordon MF, Mercandetti M. Carbon monoxide poisoning producing purely cognitive and behavioral sequelae. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1989;2:145-152.

Giladi N, Burke RE, Kostic V, Przedborski S, Gordon M, Hunt A, Fahn S. Hemiparkinsonism-hemiatrophy syndrome: clinical and neuroradiologic features. Neuro 1990;40:1731-1734.

Gordon MF, Gerstenblitt D. The use of free phenytoin levels in averting phenytoin toxicity (letter). New York State Journal of Medicine 1990;90:469-470.

Gordon MF, Allon M, Coyle PK. Drug-Induced Meningitis. Neurology 1990;40:163-4.

Szymanski S, Munne R, Gordon MF, Lieberman J. A selective review of recent advances in the management of tardive dyskinesia. Psychiatric Annals 1993;23:209-215.

Gordon MF, Diaz-Olivo R, Hunt AL, Fahn S. Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders. Movement Disorders 1993;8:484-488.

Bressman SB, Heiman GA, Nygaard TG, Ozelius LJ, Hunt AL, Brin MF, Gordon MF, Moskowitz CB, de Leon D, Burke RE, Fahn S, Risch NJ, Breakefield XO, Kramer PL. A study of idiopathic torsion dystonia in a non-Jewish family: evidence for genetic heterogeneity. Neurology 1994:44:283-287.

Parkinson Study Group. A Controlled trial of lazabemide (Ro-19-6327) in levodopa-treated Parkinson's disease. Arch Neurol 1994;51:342-347.

Koller WC, Busenbark K, Miner K, The Essential Tremor Study Group. The relationship of essential tremor to other movement disorders; report on 678 patients. Ann Neurol 1994;35:717-723.

Gordon MF, Weiner WJ, Koller WC, Rao TH, Chehebar V, Dickson DW. What is it? Case 2, 1994: Parkinsonism and cognitive impairment. Movement Disorders 1994;9:679-686.

Gordon MF, Abrams RI, Rubin DB, Barr WB, Correa DD. Bismuth toxicity. (Correspondence). Neurology 1994;44:2418.

Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, Lieberman JA. The use of clozapine in neurologic disorders. J Clin Psychiatry 1994;55:9 (suppl B):98-101.

Gordon MF, Abrams RI, Rubin DB, Barr WB, Correa DD. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus (brief report). Movement Disorders 1995;10:220-222.

Gordon MF, Bressman S, Brin MF, de Leon D, Warburton D, Yeboa K, Fahn S. Dystonia in a patient with deletion of 18q (brief report). Movement Disorders 1995;10:496-499.

Chatterjee A, Gordon MF, Giladi N, Trosch R. Botulinum toxin for tardive dystonia. Journal of Clinical Psychopharmacology. 1997;17:497-8.

Klein, C, Page CE, LeWitt P, Gordon MF, et al. Genetic analysis of three patients with an 18p-syndrome and dystonia. Neurology 1999;52:649-651.

Sharfstein SR, Gordon MF, Libman RB, Malkin ES. Adult-onset MELAS presenting as herpes encephalitis. Archives of Neurology 1999;56:241-243.

Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.

Frucht S, Rogers JD, Greene PE, Fahn S, Gordon MF. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (letter to the editor) 2000;54:276-77.

Schwarz W, Gordon MF. Defining Dystonia. ADVANCE for Physical Therapists & PT Assistants. Part I:1999 (Aug. 16): 33-34, Part II:1999(Aug. 30);33-34.

Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson's Disease in a sample without *parkin* mutations. American Journal of Human Genetics 2002;71:124-135.

Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, McAfee A, Ruffing K, Thompson B, Williams M, Lee CH, Turkel C. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Archives of Physical Medicine & Rehabilitation. 2002;83(10):1349-54.

The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: The TEMPO study. Archives of Neurology 2002;59:1937-1943.

Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group. Linkage stratification and mutation analysis at the *parkin* locus identifies mutation positive Parkinson disease families. Journal of Medical Genetics. 2002;39:489-92.

Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. New England Journal of Medicine. 2002;347:395-400.

Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. New England Journal of Medicine. 2003;348(3):258-259 (letter to the editor).

Parkinson Study Group (Siderowf A, primary author). Test-retest reliability of the Unified Parkinson's Disease Rating Scale: results from a multicenter clinical trial. Movement Disorders. 2003:18:275-279.

Reider CR, Halter CA, Castellucio PF, Oakes D, Foroud T, and the Parkinson Study Group. Reliability of reported age at onset for Parkinson's disease. Movement Disorders 2003;18(3):275-9.

Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC, and the Parkinson Study Group. Heterozygosity for a mutation in the *parkin* gene leads to later onset Parkinson disease. Neurology 2003;60:796-801.

Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, and the Dystonia Study Group. Rating Scales for Dystonia: A multi-center assessment. Movement Disorders. 2003;18:303-312.

Pankratz P, Nichols WC, Uniacke SK, Halter SK, and the Parkinson Study Group. Significant linkage of Parkinson's disease to chromosome 2q36-37. American Journal of Human Genetics. 2003;72:1053-1057.

Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud TM, and the Parkinson Study Group. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Human Molecular Genetics 2003;16;12(20):2599-2608.

Parkinson Study Group, Stern M. A controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study). Ann Neurol 2003:54(7);S27.

The Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease (TEMPO). Archives of Neurology. 2004;61:561-566.

Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud TM, Nichols WC, and the Parkinson Study Group. Genes influencing Parkinson disease onset: Replication of *PARK3* and identification of novel loci. Neurology 2004;62:1616-1618.

Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C; BOTOX Poststroke Spasticity Study Group. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63(10):1971-1973.

Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurol 2004;62:330-332.

Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group. Evaluation of the Role of Nurr1 in a Large Sample of Familial Parkinson's Disease. Movement Disorders 2004;19(6):649-655.

Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T for the Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson disease. Lancet. 2005: Jan 29-Feb 4;365(9457):410-2.

Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin, AS, Eidelberg D. FDG-PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26(3):912-921.

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations. The PRESTO Study. Arch Neurol 2005;62:241-248.

Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC, and the Parkinson Study Group-PROGENI Investigators. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Movement Disorders. Mov Disord 2006;21:45-49.

Siderowf A, Eberly S, Oakes D, Shoulson I on behalf of the Parkinson Study Group. Authors' response: Re-examination of the TEMPO study. Arch Neurol 2005;62(8):1320-1321.

Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, and **BoNTA**-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clinic Proceedings. 2005;80(9):1126-37.

Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW. Lrrk2 and Lewy body disease. Ann Neurol. 2006;59(2):388-93.

Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I and the Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006;66:1427-1429.

Biglan K, Schwid S, Eberly S, Blindauer K, Fahn F, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, and the Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006; 21(5):616-623.

Zgaljardic DJ, Borod JC, Foldi NS, Mattis PJ, Gordon MF, Feigin A, Eidelberg D. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. Journal of Clinical and Experimental Neuropsychology. 2006;28(7):1127-44.

Mentis MJ, Delalot D, Naqvi H, Gordon MF, Gudesblatt M, Edwards C, Donatelli L, Dhawan V, Eidelberg D. Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease. Mov Disord. 2006 Apr;21(4):549-55.

Gordon MF, Barron R. Effectiveness of repeated treatment with botulinum toxin type A across different conditions. South Medical Journal. 2006;99(8):853-61.

The Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006;66:408-410.

Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M, The Parkinson Study Group. A randomized controlled trial of etilevodopa in Parkinson's disease with motor fluctuations. Archives of Neurology 2006;63(2):210-216.

Jankovic J, Hunter D, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006;67:2233–2235.

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC, Parkinson Study Group Progeni Investigators. Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson disease. Movement Disorders. 2006:21(12):2257-60.

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC, Parkinson Study Group-PROGENI Investigators. Mutations in DJ-1 are rare in familial Parkinson disease. Neuroscience Letters. 2006: 408(3):209-13.

Elmer L, Schwid S, Eberly L, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, and Parkinson Study Group TEMPO and PRESTO Investigators. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. Journal of the Neurological Sciences. 2006:248;78-83.

Yablon SA. Brashear A. Gordon MF. Elovic EP. Turkel CC. Daggett S. Liu J. Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clinical Therapeutics. 2007:29(4):683-90.

Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, and Parkinson Study Group- PROGENI Investigators. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Movement Disorders. 2007:22(2):254-7.

Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter C, Rudolph A, Shults CW, Foroud T and the Parkinson Study Group-PROGENI Investigators. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 2007;69:1737-1744.

The Parkinson Study Group PRECEPT Investigators. The mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson's Disease. Neurology 2007;69:1480-90.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A and the Parkinson Study Group PRECEPT Investigators. Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. Arch Neurol. 2008;65(6):716-723.

Zgaljardic DJ, Borod JC, Foldi NS, Rocco M, Mattis PJ, Gordon MF, Feigin A, Eidelberg D. Relationship between self-reported apathy and executive dysfunction in non-demented patients with Parkinson's disease. Cognitive & Behavioral Neurology. 2007;20(3):184-92.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M for the CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Movement Disorders 2008;23(10):1353-1360.

Shoulson I, Lang AE, Bozyczko-Coyne, on behalf of the Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson's Disease (Correspondence). Neurology 2008;71:462-3.

White WB, Salzman P, Schwid SR; for the Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off" (PRESTO) Parkinson Study Group. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson Disease. Hypertension 2008;52:587-593.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, on behalf of the TEMPO Open-label Study Group (see author list). Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement Disorders. 2009;24(4):564-573.

Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A, and BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spacticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009; 80(4):380-5.

Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC for the Parkinson Study Group-PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009;73;279-286.

Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Parkinson Study Group-PROGENI Investigators. Variation in GIGYF2 is not associated with Parkinson disease. Neurology 2009 72(22):1886-92.

Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Parkinson Study Group-PROGENI Investigators. Variation in GIGYF2 is not associated with Parkinson disease. Neurology 2009 72(22):1886-92.

Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Pfeiffer RF, Foroud T and Parkinson Study Group PROGENI Investigators. Alpha-Synuclein and Familial Parkinson's Disease. Mov Disord 2009;24(8):1125-1131.

Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, PSG–PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories (2009) Genomewide Association Study for Susceptibility Genes Contributing to Familial Parkinson Disease. Hum Genet 124(6):593-605.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord 2009;24(16):2370-2378.

Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T; PROGENI Investigators, Coordinators and Molecular Genetic Laboratories; GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009 Sep 22;10:98.

Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose pramipexole in early Parkinson's disease: A randomized, placebo-controlled trial. Movement Disorders published on-line (October 2010). (Please note that as Trial Clinical Monitor, I am a listed author [Appendix A] based on my contributions to this study and paper.)

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I, and the PSG PRECEPT Investigators. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Movement Disorders 2010;25(12): 1801–1808.

Bertoni JM, Arlette JP, Fernandez HF, …Wolf JE, for the North American Parkinson's and Melanoma Survey Investigators. Increased Melanoma Risk in Parkinson Disease A Prospective Clinicopathological Study. Arch Neurol. 2010;67(3):347-352.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE, the Parkinson Study Group DATATOP and PRECEPT Investigators. Predictors of time to requiring dopaminergic treatment in two Parkinson's disease cohorts. Mov Disord 2011;26(4):608-613.

Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, Destefano AL; the PSG–PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy Number Variation in Familial Parkinson Disease (2011) PLoS One. 2011;6(8):e20988.

Ondo WG, Hossain MM, Gordon MF, Reess J. Predictors of Placebo Response in Restless Legs Syndrome Studies. Neurology 2013;81:193-194.

Stephenson, D; Aviles, E, Bain, LJ, Brumfield, M, Carrillo, M, Comery, TA, Compton, C, Corrigan, B, Gordon, MF, Jack, CR, Katz, R, Logovinsky, V, Satlin, A, Marek, K, Nicholas, T, Polhamus, D, Angersbach, BS, Raghavan, N, Romano, G, Romero, K, Shaw, L, Woodcock, J, Vradenburg, G, Isaac, M. Coalition Against Major Diseases: Precompetitive collaborations and regulatory paths to accelerating drug development for neurodegenerative diseases. Therapeutic Innovation & Regulatory Science Nov. 2013;47(6): 632-638.

Berger JR, Choi D, Kaminski HJ, Gordon MF, Hurko O, D'Cruz O, Pleasure SJ, Feldman EL. Importance and Hurdles to Drug Discovery for Neurological Disease. Annals of Neurology 2013;74:441-446.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D, and The Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD Subjects in the PRECEPT Study. Neurology 2014;82:1791-1797.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I, and the Parkinson Study Group PRECEPT Investigators. Impact of Disclosure of Individual Imaging Results in a Multi-Center Parkinson Clinical Trial. J Parkinsons Dis. 2014 Jul 25 (epub ahead of print)

Hauser RA and Gordon MF as co-primary authors, Mizuno Y, Poewe W, Barone B, Schapira A, Rascol O, Debieuvre C, Fräßdorf, M. Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. Parkinson's Disease, Volume 2014, Article ID 467131, 8 pages, http://dx.doi.org/10.1155/2014/467131 (on-line only).

Wang Y, Sun S, Zhu S, Liu C, Liu Y, Di Q, Shang H, Ren Y, Lu C, Gordon MF, Juhel N, Chen S, for the Pramipexole ER Study Team. The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study. Translational Neurodegeneration 2014 Jun 2;3:11. doi: 10.1186/2047-9158-3-11. eCollection 2014.

Hayes RP, Blum SI, Gordon MF, Piault E, Burke LB, Slagle AF, Coons SJ. The Patient-Reported Outcome (PRO) Consortium: Lessons Learned Along the Path to PRO Instrument Qualification. Therapeutic Innovation & Regulatory Science 2015;49(1):132-138. Online 14 Sept. 2014 DOI: 10.1177/2168479014549858 http://dij.sagepub.com/content/early/2014/09/12/2168479014549858).

Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang S-J, Sauer J-M, Marier JF, Corrigan B, Rogers J, Heerspink HJL, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T. Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J Pharmacokinet Pharmacodyn. 2014;41(6):545-552. Online 07 Oct. 2014 DOI 10.1007/s10928-014-9390-0.

Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P, and E.U./U.S./CTAD Task Force Members (I am a listed member). Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. April 2015. http://dx.doi.org/10.14283/jpad.2015.55.

Stephenson D, Brumfield M, Romero K, Woodcock J, Zineh I, Reiman EM, Tanner C, Mohs R, Koroshetz W, Nicholas T, Bain LJ, Romero K, Hill D, Shaw L, Luthman J, Ropacki M, Meibach R, Loupos P, Marek K, Hendrix J, Karran E, Vradenburg G, Motohashi K, Cedarbaum JM, Gordon MF. Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of The Precompetitive Consortium, Coalition Against Major Diseases. Proceedings of CAMD-FDA Annual Scientific Meeting, FDA, Silver Spring, MD, October 20, 2014. J Alzheimer's Dis Parkinsonism 2015;5:183. doi: 10.4172/2161-0460.1000183

Gordon MF, Lenderking WR, Duhig A, Chandler J, Lundy JJ, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S, Frank L, on behalf of Patient-Reported Outcome Consortium's Cognition Working Group. Development of a patient-reported outcome (PRO) instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment (MCI): the qualitative research phase. Alzheimer's & Dementia, Epub June 13, 2015. http://www.alzheimersanddementia.com.marlin-qa.literatumonline.com/article/S1552-5260(15)00186-7/abstract. DOI: http://dx.doi.org/10.1016/j.jalz.2015.04.008. 2016;12:75-84.

Soto M, Abushakra S, Cummings J, Siffert J, Robert P, Vellas B, Lyketsos CG, and E.U./U.S./ CTAD Task Force Members (I am a listed member). Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: focus on agitation and aggression. A Report from the EU/US/CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 2015;2(3):184-188.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, and the Amyloid Biomarker Study Group {of which I am a listed author}. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015; 313(19):1924-38. doi: 10.1001/jama.2015.4668.

Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little MA, Friend S, Lovestone S, Morris HR, Grosset D, Sutherland M, Gallacher J, Williams-Gray C, Bain LJ, Avilés E, Marek K, Toga AW, Stark Y, Gordon MF, Ford S. Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease. Summary of Parkinson's UK, London Workshop, May 1-2, 2014, co-organized by the Coalition Against Major Diseases (CAMD). Journal of Parkinson's Disease 2015;5(3): 581-594. DOI 10.3233/JPD-150570

Tang EYH, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BCM. Current developments in dementia risk prediction modelling: An updated systematic review. PLoS ONE 10(9) September 3, 2015;1-31. DOI:10.1371/journal.pone.0136181

Alexander M, Perera G, Ford L, Arrighi HM, Foskett N, Debove C, Novak G, Gordon MF. Age-stratified prevalence of mild cognitive impairment and dementia in European populations, a systematic review. Journal of Alzheimer's Disease 2015; 48(2):355-359. DOI: 10.3233/JAD-150168.

Haas M, Stephenson D, Romero K, Gordon MF, Zach N, Geerts H, on behalf of the Brain Health Modeling Initiative. Big data to smart data in AD: Real-world examples of advanced modeling and simulation. Alzheimer's & Dementia 2016;12:1022-1030. http://www.alzheimersanddementia.com/article/S1552-5260(16)30279-5/pdf

Geerts H, Dacks PA, Devanarayan V, Haas M, Khachaturian Z, Gordon MF, Maudsley S, Romero K, Stephenson K, on behalf of the Brain Health Modeling Initiative (BHMI). From big data to smart data in Alzheimer's Disease. The Brain Health Modeling

Initiative to foster actionable knowledge. Alzheimer's & Dementia 2016;12:1014-1021. http://www.alzheimersanddementia.com/article/S1552-5260(16)30246-1/pdf

Seiple W, Jennings D, Rosen RB, Borchert L, Canale L, Fagan N, Gordon MF. Ophthalmologic baseline characteristics and 2-year ophthalmologic safety profile of pramipexole IR compared with ropinirole IR in patients with early Parkinson's disease. Parkinson's Disease, vol. 2016, Article ID 8298503, 14 pages, 2016. doi:10.1155/2016/8298503. Epub 2016 Dec 18.

Arnerić SP, Batrla-Utermann R, Beckett L, …, Gordon MF, et al. (alphabetized list of authors). Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Journal of Alzheimer's Disease. 2017;55:19–35. DOI 10.3233/JAD-160573.

Ropacki MT, Hannesdottir K, Hendrix S, Gordon MF, Stephenson D, Coons SJ, Stern RA, on behalf of the Critical Path Institute's Coalition Against Major Diseases and the Patient-Reported Outcome Consortium Cognition Working Group. Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients. Therapeutic Innovation & Regulatory Science. Feb. 2017 on line. DOI: 10.1177/2168479016689712.

Bos I, Vos SJ, Frolich L, et al (Gordon MF as named author). The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging 2017;56(Aug):33-40. http://dx.doi.org/10.1016/j.neurobiolaging.2017.03.034. Epub 2017 Apr 8.

Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, Foskett N, Gini R, Gordon MF, Gungabissoon U, Mayer M-A, Novak G, Rijnbeek P, Trifirò G, van der Lei J, Visser PJ, Stewart R. Dementia prevalence and incidence in a federation of European Electronic Health Record databases – the European Medical Informatics Framework resource. Alzheimer's & Dementia. 2018 Feb;14(2):130-139. http://dx.doi.org/10.1016/j.jalz.2017.06.2270. Epub 2017 July 21.

Arnerić SP, Cedarbaum JM, Khozin SA, Papapetropoulos S, Hill DL, Ropacki M, Rhodes J, Dacks PA, Hudson LD, Gordon MF, Kern VD, Romero K, Vradenburg G, Au R, Karlin DR, Facheris MF, Fitzer-Attas CJ, Vittolo OV, Wang J, Miller BM, Kaye JA. Biometric monitoring devices for assessing endpoints in clinical trials: Developing an ecosystem. Nature Reviews Drug Discovery Oct.;16(10):736. doi:10.1038/nrd.2017.153. Epub 22 Sep 2017.

Hake AM, Dacks PA, Arnerić SP, The Coalition Against Major Diseases Informed Consent Form Working Group. Concise informed consent to increase data and biospecimen access may accelerate innovative Alzheimer's disease treatments. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017;3:536-541.

Jansen WJ, Ossenkoppele R, Tijms BM,…, Amyloid Biomarker Study Group {of which I am a listed author}, Scheltens P, Verhey FR, Visser PJ. Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry. 2018;75(1):84-95. Epub November 29, 2017. doi:10.1001/jamapsychiatry.2017.3391.

ten Kate M, Redolfi A, Peira E, …, Gordon MF, …, Visser PJ, Barkhof F. MRI predictors of amyloid pathology: results from the EMIF-AD multimodal biomarker discovery study. Alzheimer's Research and Therapy. 2018;10:100 https://doi.org/10.1186/s13195-018-0428-1.

Legdeur N, Badissi M, Carter SF, …, Gordon MF, …, Visser PJ. Resilience to cognitive impairment in the oldest-old: design of the European Medical Information Framework (EMIF) 90+ Study. BMC Geriatrics. 2018;18:289. https://doi.org/10.1186/s12877-018-0984-z.

Cohen S, Waks Z, Elm JJ, Gordon MF, Grachev ID, Navon-Perry L, Fine S, Grossman I, Papapetropoulos S, Savola J-M. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease. BMC Medical Informatics and Decision Making. 2018;18:138. https://doi.org/10.1186/s12911-018-0714-7

Abstracts

138 accepted presentations from 1990 to April 17, 2019. List available on request

Chapters

Gordon MF. Bismuth. In Experimental and Clinical Neurotoxicology: second edition. PS Spencer, HH Schaumburg, and AC Rudolph, eds. Oxford University Press. New York. 2000: 236-239.

Gordon MF. Toxin and Drug-Induced Myoclonus. In: Advances in Neurology. Vol. 89: Myoclonus and the Paroxysmal Dyskinesias. S Fahn, SJ Frucht, M Hallett, and DD Truong, eds. Lippincott Williams & Wilkins. New York. 2002: 49-76.

The Dystonia Study Group. Rating Scales for Dystonia: Assessment of the Reliability of 3 scales. In: Advances in Neurology, Volume 94: Dystonia 4. S Fahn, M Hallett, and M DeLong, eds. Lippincott Williams & Wilkins. New York. 2003: 329-336.

Gordon MF, Leder A. Serotonin Syndrome. In: Movement Disorder Emergencies: Diagnosis and Treatment. S Frucht and S Fahn, eds. Humana Press, Totowa, NJ. 2005: 175-185.

Koo BB, Gordon MF, Gordon ML. Extrapyramidal syndromes related to neuroleptics. In Handbook of Medicine in Psychiatry. P Manu, RE Suarez and BJ Barnett, eds. American Psychiatric Publishing. Arlington, VA. 2006: 195-207.

Gordon MF, Leder A. Serotonin Syndrome. In: Movement Disorder Emergencies: Diagnosis and Treatment (2nd Edition). SJ Frucht, ed. Humana Press, New York. 2013: 217-239.